These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 9536144)
1. Iatrogenic complications of depot antipsychotics given to unfamiliar patients. Wilson RN J R Soc Med; 1998 Jan; 91(1):38-40. PubMed ID: 9536144 [No Abstract] [Full Text] [Related]
2. Tolerability of low dose neuroleptics: a case control study of flupenthixol. Fritze J; Spreda I Eur Neuropsychopharmacol; 1997 Nov; 7(4):261-6. PubMed ID: 9443657 [TBL] [Abstract][Full Text] [Related]
3. Neuroleptic malignant syndrome in 12 of 9,792 Chinese inpatients exposed to neuroleptics: a prospective study. Deng MZ; Chen GQ; Phillips MR Am J Psychiatry; 1990 Sep; 147(9):1149-55. PubMed ID: 1974744 [TBL] [Abstract][Full Text] [Related]
6. Depot flupenthixol decanoate for schizophrenia or other similar psychotic disorders. Quraishi S; David A Cochrane Database Syst Rev; 2000; (2):CD001470. PubMed ID: 10796442 [TBL] [Abstract][Full Text] [Related]
7. [Iatrogenic extrapyramidal disorders]. Ludin HP Schweiz Med Wochenschr; 1990 Jun; 120(23):855-8. PubMed ID: 1972812 [TBL] [Abstract][Full Text] [Related]
8. Flupenthixol decanoate and injection site abscesses in an obese patient. Andrade C Aust N Z J Psychiatry; 2002 Aug; 36(4):561-2. PubMed ID: 12169162 [No Abstract] [Full Text] [Related]
9. Clinical and neurobiologic implications of antipsychotic-induced movement disorders. Rubin EH; Zorumski CF Compr Ther; 1986 Oct; 12(10):61-7. PubMed ID: 2877769 [No Abstract] [Full Text] [Related]
10. Long-acting injectable risperidone: safety and efficacy in stable patients switched from conventional depot antipsychotics. Turner M; Eerdekens E; Jacko M; Eerdekens M Int Clin Psychopharmacol; 2004 Jul; 19(4):241-9. PubMed ID: 15201572 [TBL] [Abstract][Full Text] [Related]
13. Atypical neuroleptic malignant syndrome: A systematic review of case reports. Singhai K; Kuppili PP; Nebhinani N Gen Hosp Psychiatry; 2019; 60():12-19. PubMed ID: 31299470 [No Abstract] [Full Text] [Related]
14. Olanzapine-induced neuroleptic malignant syndrome with mental retardation. Margolese HC; Chouinard G Am J Psychiatry; 1999 Jul; 156(7):1115-6. PubMed ID: 10401467 [No Abstract] [Full Text] [Related]
15. Movement disorders with neuroleptic drug treatment. Tarsy D Psychiatr Clin North Am; 1984 Sep; 7(3):453-71. PubMed ID: 6148742 [TBL] [Abstract][Full Text] [Related]
16. Prevalence of obesity in patients receiving depot antipsychotics. Silverstone T; Smith G; Goodall E Br J Psychiatry; 1988 Aug; 153():214-7. PubMed ID: 2908236 [TBL] [Abstract][Full Text] [Related]
17. Risk factors for the neuroleptic malignant syndrome. Kirkpatrick B; Edelsohn GA Psychiatr Med; 1984 Dec; 2(4):371-81. PubMed ID: 6152857 [No Abstract] [Full Text] [Related]
18. Incidence of tardive dyskinesia in patients receiving depot neuroleptic injection. Gibson AC Acta Psychiatr Scand Suppl; 1981; 291():111-6. PubMed ID: 6113729 [No Abstract] [Full Text] [Related]
20. A protocol for the diagnosis and treatment of extrapyramidal symptoms of neuroleptic drugs. Bickal T Nurse Pract; 1987 Jan; 12(1):25, 29, 32 passim. PubMed ID: 2880325 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]